SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway

SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway

Lenvatinib has become the first-line therapy in advanced hepatocellular carcinoma (HCC), but its efficacy is still limited because of the inevitable development of resistance. It has been reported that cellular cholesterol levels are associ...

Full description

Bibliographic Details
Main Authors: Fan Minghao, Chen Zhenmei, Shao Weiqing, Chen Yiran, Lin Zhifei, Yi Chenhe, Li Yitong, Lu Lu, Zhou Yu, Lin Jing
Format: Article
Language:English
Published: China Science Publishing & Media Ltd. 2023-07-01
Series:Acta Biochimica et Biophysica Sinica
Subjects:
hepatocellular carcinoma
SREBP2
lenvatinib
betulin
cholesterol
interleukin-1β
Online Access:https://www.sciengine.com/doi/10.3724/abbs.2023122

Internet

https://www.sciengine.com/doi/10.3724/abbs.2023122

Similar Items